Comparative LDL-C Reduction and Cardiovascular Outcomes With PCSK9-Pathway Therapies: A Systemic Review and Network Meta-Analysis
Proprotein convertase subtilisin/kexin type 9 (PCSK9)–targeted therapies substantially reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. While monoclonal antibodies have demonstrated outcome benefits, newer agents including siRNA and small-protein inhibitors lack mature event-driven data...